Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
February 5, 2007
- Toyama Starts PI Trial for Anti-Flu Drug T-705
February 5, 2007
- NEW PRODUCTS
February 5, 2007
- Fewer than Half of All Women Aware that Pill Can Boost Fertility
February 5, 2007
- Reexamination Period to Be Extended to Eight Years: PFSB
February 5, 2007
- Ajinomoto Licenses Novel Diabetes Treatment to BI
February 5, 2007
- Government-private Sector Dialogue Begins
February 5, 2007
- Kansai Bio-Cluster Is No. 4 in the World: Prof. Morishita
February 5, 2007
- PM Abe Calls For Strategic Support of Pharma Industry in Policy Speech
February 5, 2007
- Japan Should Participate in More Multinational Trials: Dr Sato of PMDA
January 29, 2007
- MPC, Tanabe Discuss Merger -Merger to Give Birth to 6th Largest Japanese Company-
January 29, 2007
- Study Group for Early Approval of Drugs to Focus on Microdosing Studies
January 29, 2007
- 58.2% Aware of DTC Disease Education Ads
January 29, 2007
- R&DNEWS IN BRIEF
January 29, 2007
- Globalization Essential to Growth of Domestic Bioventures: Mr Yamazaki
January 29, 2007
- Novartis Begins Independent Sale of OTC Drugs
January 29, 2007
- Life Science to Account for 10-15% of Sales at Toyobo in 2010
January 29, 2007
- SELF-MEDICATION NEWS IN BRIEF
January 29, 2007
- BUSINESS NEWS IN BRIEF
January 29, 2007
- Nichi-Iko Aims at Sales of \43.0 Bil. in 2009
January 29, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…